🎯 Pipeline Prediction Dashboard

Generated: 2026-02-16T07:31:20 | Snapshot: 2026-02-13 | 242 Active Deals

7
🟢 Strong (70%+)
12
🔵 Healthy (50-69%)
183
🟡 At Risk (30-49%)
40
🔴 Critical (<30%)
Total Pipeline Value
€242,323,346
Expected Value (probability-weighted)
€80,928,764
Filter:
Deal Assignee Stage Value Prob % Expected Category Score Breakdown
Bayer US - Lynkuet (Elinzanetant) Karen VanOverberghe Qualification | 5% €421,260 74% €311,732 Strong Vel: 20/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: 6/10
Bayer US Nubeqa Karen VanOverberghe Qualification | 5% €421,260 74% €311,732 Strong Vel: 20/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: 6/10
Boehringer Ingelheim Jascayd Patient Finder Karen VanOverberghe Discovery | 10% €421,259 74% €311,732 Strong Vel: 20/20 | DM: 7/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: 4/10
Merck Patient Finder PAH(Oncology) Winrevair US Karen VanOverberghe Discovery | 10% €421,260 73% €307,520 Strong Vel: 20/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: 5/10
Relevate health Jacob Plummer Discovery | 10% €84,252 73% €61,504 Strong Vel: 20/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: 5/10
Etsilat Adel Baluch Discovery | 10% €500,000 71% €355,000 Strong Vel: 20/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 15/15 | Call: -/10
Pfizer - Nurtec Eran Desheh Discovery | 10% €500,000 70% €350,000 Strong Vel: 20/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 15/15 | Call: 4/10
Biogen US Ashley Cudini Qualification | 5% €421,260 69% €290,669 Healthy Vel: 20/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 15/15 | Call: 4/10
Dronline Adel Baluch Discovery | 10% €300,000 69% €207,000 Healthy Vel: 20/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 15/15 | Call: 5/10
PracticePlusGroup Adel Baluch Discovery | 10% €350,000 69% €241,500 Healthy Vel: 14/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: -/10
GHOL Johannes Vonhuelsen Qualification | 5% €0 67% €0 Healthy Vel: 14/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 15/15 | Call: -/10
VERTEX | AMKD | US Ashley Cudini Qualification | 5% €421,260 64% €269,606 Healthy Vel: 20/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 15/15 | Call: -/10
argenx US Vyvgart gMG Ashley Cudini Qualification | 5% €421,260 61% €256,969 Healthy Vel: 20/20 | DM: 2/20 | Act: 10/20 | Com: 8/15 | Age: 15/15 | Call: -/10
Jazz Pharmaceuticals US- Xywav Ashley Cudini Qualification | 5% €421,260 61% €256,969 Healthy Vel: 20/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 15/15 | Call: 3/10
UCB MG-Rare Patient Finder Karen VanOverberghe Qualification | 5% €421 56% €236 Healthy Vel: 18/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 15/15 | Call: 4/10
Biogen - Vumerity Usaid Cheema Qualification | 5% €500,000 54% €270,000 Healthy Vel: 6/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Bayer Visanne Patient Finder Karen VanOverberghe Qualification | 5% €211,472 50% €105,736 Healthy Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Merck Patient Finder Portfolio Exploration Karen VanOverberghe Qualification | 5% €210,629 50% €105,315 Healthy Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Takeda | Narcolepsy | investigational | US - Phase Usaid Cheema Qualification | 5% €5,055,120 50% €2,527,560 Healthy Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Doctor Care Anywhere Adel Baluch Qualification €350,000 49% €171,500 At Risk Vel: 14/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 15/15 | Call: 5/10
GSK Product Exploration Karen VanOverberghe Qualification | 5% €210,630 49% €103,209 At Risk Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Ipsen Patient Finder Karen VanOverberghe Qualification | 5% €210,630 49% €103,209 At Risk Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Merck | Oncology & PAH | Keytruda & Winrevair | US Karen VanOverberghe Qualification | 5% €421,260 49% €206,417 At Risk Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
MSD | PAH | SOTATERCEPT | DE - Phase 2 Usaid Cheema Qualification | 5% €6,000,000 48% €2,880,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Philipps-Universität Marburg / Universitätskliniku Johannes Vonhuelsen Qualification | 5% €0 48% €0 At Risk Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: -/10
BMS - Patient finder Camzyos Eran Desheh Discovery | 10% €250,000 47% €117,500 At Risk Vel: 6/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
Resmed Phase 2 Jacob Plummer Qualification | 5% €2,527,560 47% €1,187,953 At Risk Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
SANOFI | Diabetes | TZIELD | US - Phase 2 Eran Desheh Discovery | 10% €2,527,560 47% €1,187,953 At Risk Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
AstraZeneca | aHUS, PNH, HPP | UAE - Phase 2 Eran Desheh Qualification | 5% €5,055,120 46% €2,325,355 At Risk Vel: 6/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
AstraZeneca | ATTR-CM | UAE - Phase 2 Eran Desheh Qualification | 5% €5,055,120 46% €2,325,355 At Risk Vel: 6/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Biogen - leqembi Usaid Cheema Qualification | 5% €500,000 46% €230,000 At Risk Vel: 6/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
AbbVie - Rinvoq Usaid Cheema Qualification | 5% €421,260 44% €185,354 At Risk Vel: 6/20 | DM: 10/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
AbbVie - Vraylar Usaid Cheema Qualification | 5% €500,000 44% €220,000 At Risk Vel: 6/20 | DM: 10/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Biogen Germany FA extension Eran Desheh Discovery | 10% €2,100,000 44% €924,000 At Risk Vel: 2/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Biogen Italy Eran Desheh Qualification | 5% €350,000 44% €154,000 At Risk Vel: 2/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Biogen | Friedreichs Ataxia | Global - Phase 2 Eran Desheh Qualification | 5% €6,000,000 44% €2,640,000 At Risk Vel: 2/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Dubai Health (Phase 1) Simon Wolpert Qualification | 5% €1,250,000 44% €550,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
GNAL Simon Wolpert Qualification | 5% €20,500,000 43% €8,815,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
UCB Pharma S.A.  - Bimzelx Eran Desheh Qualification | 5% €500,000 43% €215,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
UCB | TK2D | investigational | US - Phase 2 Jacob Plummer Qualification | 5% €5,055,120 43% €2,173,702 At Risk Vel: 6/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Sumitomo-Gemtesa Patient FInder Karen VanOverberghe Qualification | 5% €210,630 42% €88,465 At Risk Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 3/15 | Call: 4/10
Alexion Pharmaceuticals - Ultomiris Usaid Cheema Qualification | 5% €500,000 41% €205,000 At Risk Vel: 6/20 | DM: 7/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Alkermes - Libalvi Usaid Cheema Qualification | 5% €500,000 41% €205,000 At Risk Vel: 6/20 | DM: 7/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Ipsen - Sohonos Eran Desheh Qualification | 5% €421,260 41% €172,717 At Risk Vel: 6/20 | DM: 5/20 | Act: 12/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Kyowa Kirin - Phase 1 Eran Desheh Discovery | 10% €500,000 41% €205,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 3/15 | Call: 5/10
BMS Portfolio Exploration Digital Health Team Pati Karen VanOverberghe Qualification | 5% €210,630 40% €84,252 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Glenmark Pharma Jacob Plummer Qualification | 5% €1 40% €0 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Takeda - Alunbrig Usaid Cheema Qualification | 5% €500,000 40% €200,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Takeda - Eohilia Usaid Cheema Qualification | 5% €421,260 40% €168,504 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Takeda - Oveporexton Usaid Cheema Qualification | 5% €421,260 40% €168,504 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Blue Shield of California Simon Wolpert Proposal | 30% €5,476,380 39% €2,135,788 At Risk Vel: 2/20 | DM: 7/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: -/10
BMS Breyanzi Patient Finder Karen VanOverberghe Qualification | 5% €250,000 39% €97,500 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Genentach | Ocrevus Usaid Cheema Qualification | 5% €421,260 39% €164,291 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Genentech - Esbriet Usaid Cheema Qualification | 5% €500,000 39% €195,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Genentech - Xolair Usaid Cheema Qualification | 5% €500,000 39% €195,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
HCF Hospitals Contribution Fund Jacob Plummer Qualification | 5% €800,000 39% €312,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Ipsen Patient Finder | Bylvay and Rare in Liver Karen VanOverberghe Qualification | 5% €421,260 39% €164,291 At Risk Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
J&J Immunology (Stelara) US - Phase 1 Eran Desheh Qualification | 5% €421,260 39% €164,291 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
J&J Immunology (Tremfya) US - Phase 1 Eran Desheh Qualification | 5% €421,260 39% €164,291 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Lilly Kisunla Patient Finder Karen VanOverberghe Qualification | 5% €210,630 39% €82,146 At Risk Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Novartis - Cosentyx (E2E Care Journey) Karen VanOverberghe Qualification | 5% €210,630 39% €82,146 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Novartis Fabhalta Patient Finder Karen VanOverberghe Qualification | 5% €500,000 39% €195,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Novartis Kesimpta Patient Finder Karen VanOverberghe Qualification | 5% €500,000 39% €195,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Roche - Piasky Usaid Cheema Qualification | 5% €500,000 39% €195,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Roche | Neurology & Oncology | Global Eran Desheh Qualification | 5% €421,260 39% €164,291 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Roche - Evrysdi Usaid Cheema Qualification | 5% €500,000 39% €195,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Voramedic Johannes Vonhuelsen Contracting | 80% €200,000 39% €78,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: -/10
AstraZeneca - Breztri Aerosphere Usaid Cheema Qualification | 5% €421,260 38% €160,079 At Risk Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
AstraZeneca - Calquence Usaid Cheema Qualification | 5% €421,260 38% €160,079 At Risk Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
AstraZeneca - Farxiga Usaid Cheema Qualification | 5% €421,260 38% €160,079 At Risk Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Astrazeneca - Wainua Usaid Cheema Qualification | 5% €500,000 38% €190,000 At Risk Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
AstraZeneca AB - Wainzua Eran Desheh Qualification | 5% €500,000 38% €190,000 At Risk Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
AstraZeneca | Saphnelo | Systemic lupus erythemato Jacob Plummer Qualification | 5% €421,260 38% €160,079 At Risk Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Biogen - Spinraza Usaid Cheema Qualification | 5% €500,000 38% €190,000 At Risk Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
MSD | PAH | SOTATERCEPT | DE Eran Desheh Contracting | 80% €50,000 38% €19,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Stanford Health Care Simon Wolpert Qualification | 5% €1,432,284 38% €544,268 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Takeda | Narcolepsy | investigational | US Eran Desheh Discovery | 10% €421,260 38% €160,079 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Aetna a CVS Health Company Simon Wolpert Qualification | 5% €252,756 37% €93,520 At Risk Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
HCA-UK Adel Baluch Discovery | 10% €0 37% €0 At Risk Vel: 2/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 0/15 | Call: 6/10
Lilly Lilly Direct - Patient Finder Karen VanOverberghe Qualification | 5% €210,630 37% €77,933 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Malaffi Super App Simon Wolpert Qualification €8,000,000 37% €2,960,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Newfoundland DFD (via Orion) Simon Wolpert Discovery | 10% €1,361,727 37% €503,839 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
NHS England Adel Baluch Discovery | 10% €573,690 37% €212,265 At Risk Vel: 2/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 0/15 | Call: 6/10
RVO Health Jacob Plummer Proposal | 30% €842,520 37% €311,732 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
UCB Bimzelx (HS) Peer to Peer Engagement Patient F Karen VanOverberghe Discovery | 10% €421 37% €156 At Risk Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
AbbVie - Botox Usaid Cheema Qualification | 5% €421,260 36% €151,654 At Risk Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
AstraZeneca | PNH | UAE Eran Desheh Discovery | 10% €421,260 36% €151,654 At Risk Vel: 2/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Bristol Myers Squibb | Opdivo | Melanoma Karen VanOverberghe Qualification | 5% €421,260 36% €151,654 At Risk Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Ministry of National Guard Health Affairs (Saudi A Adel Baluch Discovery | 10% €500,000 36% €180,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Novartis Rhapsido (Hives no known triggers) Patien Karen VanOverberghe Qualification | 5% €250,000 36% €90,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 3/15 | Call: 4/10
Obeikan Health Care Adel Baluch Discovery | 10% €350,000 36% €126,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Pure Health UAE Adel Baluch Discovery | 10% €500,000 36% €180,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Amgen Ultrarare US -Actimmune (CGD) Karen VanOverberghe Discovery | 10% €210,630 35% €73,720 At Risk Vel: 2/20 | DM: 10/20 | Act: 10/20 | Com: 8/15 | Age: 3/15 | Call: 2/10
BMS - Zeposia Usaid Cheema Qualification | 5% €500,000 35% €175,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
BUPA UK Johannes Vonhuelsen Contracting | 80% €300,000 35% €105,000 At Risk Vel: 2/20 | DM: 7/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Incyte Jakafi Patient Finder Karen VanOverberghe Qualification | 5% €421,260 35% €147,441 At Risk Vel: 6/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Amgen - Evenity Usaid Cheema Qualification | 5% €500,000 34% €170,000 At Risk Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 2/10
Astellas - MYRBETIQ Usaid Cheema Qualification | 5% €500,000 34% €170,000 At Risk Vel: 6/20 | DM: 7/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: -/10
BioMarin(Amicus purchased) - Galafold (Fabry) Karen VanOverberghe Qualification | 5% €8,424 34% €2,864 At Risk Vel: 6/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 6/15 | Call: -/10
GoodApple - Menopause RFP Jacob Plummer Discovery | 10% €0 34% €0 At Risk Vel: 2/20 | DM: 5/20 | Act: 12/20 | Com: 8/15 | Age: 3/15 | Call: 4/10
Kings College London, Saudi Arabia Adel Baluch Proposal | 30% €401,583 34% €136,538 At Risk Vel: 2/20 | DM: 5/20 | Act: 16/20 | Com: 8/15 | Age: 0/15 | Call: -/10
BMS - Atrial fibrilation and thrombosis Eran Desheh Qualification | 5% €500,000 33% €165,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
BMS - Inrebic Eran Desheh Qualification | 5% €500,000 33% €165,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
BMS - Juvenile Idiopathic Arthritis (JIA) Eran Desheh Qualification | 5% €500,000 33% €165,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
BMS - Psoriatic arthritis Eran Desheh Qualification | 5% €500,000 33% €165,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
BMS - Rheumatoid arthritis Eran Desheh Qualification | 5% €500,000 33% €165,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
Merck - Gardasil 9 Usaid Cheema Qualification | 5% €421,260 33% €139,016 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
Merck - KEYTRUDA Usaid Cheema Qualification | 5% €500,000 33% €165,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
Merck - Welireg Usaid Cheema Qualification | 5% €500,000 33% €165,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10
UCB | BIMZELX | HS |Ex-US Jacob Plummer Discovery | 10% €421,260 33% €139,016 At Risk Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
UCB | TK2D | investigational | US Jacob Plummer Discovery | 10% €421,260 33% €139,016 At Risk Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
ACADIA Pharmaceuticals | Daybue | Rett syndrome Usaid Cheema Qualification | 5% €421,260 32% €134,803 At Risk Vel: 2/20 | DM: 7/20 | Act: 12/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Alexion Pharmaceuticals - Koselugo Usaid Cheema Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 7/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Angelini Pharma S.p.A - Ontozry Eran Desheh Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Astellas - VEOZAH Usaid Cheema Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 7/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Crohns Colitis Foundation Jacob Plummer Qualification | 5% €421,260 32% €134,803 At Risk Vel: 6/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Eli Lilly Nederland B.V. - Omvoh Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
J&J - Invega Usaid Cheema Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: -/10
LEO Pharma A/S - Adtralza Eran Desheh Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
LEO Pharma A/S - Anzupgo Eran Desheh Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Lilly Zepbound OSA Ptient Finder Karen VanOverberghe Qualification | 5% €210,630 32% €67,402 At Risk Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 3/15 | Call: 4/10
Novartis HS Italy Upsell Eran Desheh Qualification | 5% €105,000 32% €33,600 At Risk Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Novartis HS Spain Upsell Eran Desheh Qualification | 5% €105,000 32% €33,600 At Risk Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Patient Finder for Temple Health Randal Whitmore Qualification | 5% €421,260 32% €134,803 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Plusultra pharma GmbH - Hyftor Eran Desheh Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
Takeda - Zasocitinib Usaid Cheema Qualification | 5% €500,000 32% €160,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10
TAKEDA | Psoriasis & Psoriatic Arthritis (Phase 3) Eran Desheh Qualification | 5% €421,260 32% €134,803 At Risk Vel: 2/20 | DM: 5/20 | Act: 12/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
ALK-Abelló A/S - Eurneffy Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Alnylam Pharmaceuticals | Amvuttra | ATTR-CM Ashley Cudini Qualification | 5% €421,260 31% €130,591 At Risk Vel: 2/20 | DM: 7/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Bayer | ATTR-CM | DE Jacob Plummer Qualification | 5% €421,260 31% €130,591 At Risk Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 6/10
BMS - US Jacob Plummer Qualification | 5% €421,260 31% €130,591 At Risk Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 6/10
BMS Cobenfy Patient Finder Karen VanOverberghe Qualification | 5% €421,260 31% €130,591 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Clinical University Childrens Hospital, Latvia (BU Adel Baluch Discovery | 10% €1,000,000 31% €310,000 At Risk Vel: 2/20 | DM: 5/20 | Act: 12/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
EMD Serono | MS & Rare Disease | US Eran Desheh Qualification | 5% €421,260 31% €130,591 At Risk Vel: 2/20 | DM: 5/20 | Act: 12/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Novo Nordisk A/S - Alhemo Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Novo Nordisk A/S - Sogroya Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Novo Nordisk A/S - Zegalogue Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Ontario SOW10 Enhancement Opportunity - Condition Simon Wolpert Proposal | 30% €389,949 31% €120,884 At Risk Vel: 2/20 | DM: 5/20 | Act: 12/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Pfizer Europe MA EEIG - Litfulo Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Pfizer Europe MA EEIG - Cibinqo Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Pfizer Europe MA EEIG - Emblaveo Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Pfizer Europe MA EEIG - Hympavzi Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Pfizer Europe MA EEIG - Tivdak Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Sanofi | Nexviazyme | Pompe's disease Usaid Cheema Qualification | 5% €421,260 31% €130,591 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
UCB - Neupro Usaid Cheema Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
UCB | Bimzelx | Psoriasis & HS Jacob Plummer Qualification | 5% €421,260 31% €130,591 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Ultragenyx Germany GmbH - Evkeeza Eran Desheh Qualification | 5% €500,000 31% €155,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10
Alexion Europe SAS - Voydeya Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Amazon Health Services | United States Christine Minott Qualification | 5% €0 30% €0 At Risk Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Amivas Ireland Ltd - Artesunate Amivas Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Blue Cross Blue Shield Arizona Simon Wolpert Qualification | 5% €1,432,284 30% €429,685 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Deciphera Pharmaceuticals (Netherlands) B.V. - Qin Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Eli Lilly and Company Karen VanOverberghe Qualification €210,630 30% €63,189 At Risk Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Galderma International - Nemluvio Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Gedeon Richter Plc. - Ryeqo Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Gilead - Biktarvy Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Gilead - Descovy Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
GlaxoSmithKline - Xevudy Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
GlaxoSmithKline Trading Services Limited - Omjjara Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
GSK - Arexvy Usaid Cheema Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10
GSK - Arnuity Ellipta Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10
GSK - Flovent Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10
GSK - Shingrix Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10
Highmark RFI Simon Wolpert Qualification | 5% €1,432,284 30% €429,685 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Incyte Biosciences Distribution B.V. - Opzelura Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
InflaRx GmbH - Gohibic Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Janssen-Cilag International N.V. - Akeega Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Johnson & Johnson | Tremfya | Psoriasis total Jacob Plummer Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Laboratoires Théa - Vevizye Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Madrigal - Rezdiffra Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Medice Arzneimittel Pütter GmbH & Co. KG - Vafseo Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Moderna Biotech Spain, S.L. - mResvia Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Mundipharma GmbH - Rezzayo Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Neuraxpharm Pharmaceuticals S.L. - Tuzulby Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Norgine B.V. - Agilus Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Novartis - Kesimpta Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Novartis | drug tbd | US Eran Desheh Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Ontario SOW 9 Enhancement - OHT Mapping - Planning Simon Wolpert Proposal | 30% €123,793 30% €37,138 At Risk Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Otsuka - centanafadine Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Outlook Therapeutics Limited - Lytenava Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Pfizer- Abrysvo Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Pfizer- Comirnaty Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Pfizer- Xtandi Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Pharming | Joenja | Activated phosphoinositide 3-k Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Pierre Fabre Medicament - Obgemsa Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
PROBTP Groupe Johannes Vonhuelsen Qualification €0 30% €0 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Roche Registration GmbH - Xofluza Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Roche Registration GmbH - Ronapreve Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Santen Oy - Catiolanze Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Santhera Pharmaceuticals (Deutschland) GmbH - Agam Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Seqirus Netherlands B.V. - Fluad Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
SIFI SPA - Akantior Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10
Sumitomo - MYFEMBREE Usaid Cheema Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Sumitomo - ORGOVYX Usaid Cheema Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Swedish Orphan Biovitrum AB (publ) - Altuvoct Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Teva B.V. - BroPair Spiromax Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Teva B.V. - Seffalair Spiromax Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Teva Pharmaceutical Industries | Austedo | Tardive Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Tolmar - Fensolvi Usaid Cheema Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Vertex Pharmaceuticals (Ireland) Limited - Casgevy Eran Desheh Qualification | 5% €500,000 30% €150,000 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
VERTEX | AMKD | US - Phase 2 Jacob Plummer Qualification | 5% €5,055,120 30% €1,516,536 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Walgreens/Boots Randal Whitmore Qualification | 5% €421,260 30% €126,378 At Risk Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Centene Patient Finder Jacob Plummer Qualification | 5% €421,260 29% €122,165 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Jazz Pharma Ashley Cudini Qualification €421,260 29% €122,165 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Pfizer | ATTR-CM | DE Jacob Plummer Qualification | 5% €421,260 29% €122,165 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Trinity Life Sciences Exploration Jacob Plummer Qualification | 5% €421,260 29% €122,165 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Ontario Enhancement - Gender Neutrality Simon Wolpert Proposal | 30% €216,638 28% €60,659 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Ontario Enhancement - Health811 Post Login Experie Simon Wolpert Discovery | 10% €309,483 28% €86,655 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Ontario Enhancements Simon Wolpert Proposal | 30% €1,980,693 28% €554,594 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Ontario SOW9 Enhancement - Trusted User (Deferred Simon Wolpert Discovery | 10% €100,000 28% €28,000 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Progyny | Endometriosis | US Jacob Plummer Qualification | 5% €421,260 28% €117,953 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Roche LatAm Ashley Cudini Qualification | 5% €100,000 28% €28,000 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Upsell - PHC / Agent Simon Wolpert Qualification | 5% €1,000,000 28% €280,000 Critical Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Acorda Therapeutics | Ampyra | Multiple sclerosis Usaid Cheema Qualification | 5% €421,260 27% €113,740 Critical Vel: 6/20 | DM: 2/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10
Northwestern Medicine - International Adel Baluch Contracting | 80% €0 25% €0 Critical Vel: 2/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Risant Health Expansion [Entity C] Eric Harker Qualification | 5% €5,055,120 23% €1,162,678 Critical Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Risant Health Expansion [Entity D] Eric Harker Qualification | 5% €5,055,120 23% €1,162,678 Critical Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Risant Health Expansion [Entity E] Eric Harker Qualification | 5% €5,055,120 23% €1,162,678 Critical Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Risant Health Expansion [Entity F] Eric Harker Qualification | 5% €5,055,120 23% €1,162,678 Critical Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Fraser Health (vis Deloitte) - British Columbia Simon Wolpert Qualification | 5% €3,249,575 22% €714,906 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Health 811 SOW9 - HCC + Survey Planning + Delivery Simon Wolpert Proposal | 30% €92,845 22% €20,426 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Main Line Health Simon Wolpert Qualification €1,432,284 22% €315,102 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Novo Nordisk Global Markets Eran Desheh Discovery | 10% €500,000 22% €110,000 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Pharmeon | UW Zorg online Discovery €1,050,000 22% €231,000 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Salinas Valley Health Simon Wolpert Qualification €1,700,000 22% €374,000 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Texas Tech University Health System Qualification €758,268 22% €166,819 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
DKV Seguros Johannes Vonhuelsen Discovery | 10% €486,000 21% €102,060 Critical Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: -/10
NYU Langone DFD Simon Wolpert Qualification | 5% €1,263,780 21% €265,394 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Patient Finder for Boots UK Randal Whitmore Qualification €0 21% €0 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Saudi MoH Sehhaty App Daniel Nathrath Qualification €7,085,000 21% €1,487,850 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 4/10
Alberta Health Services - Patient Portal (via Orio Simon Wolpert Qualification | 5% €4,796,991 19% €911,428 Critical Vel: 2/20 | DM: 2/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
BCBSA Simon Wolpert Qualification €3,200,000 19% €608,000 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Blue Cross Blue Shield Michigan Simon Wolpert Qualification €5,055,120 19% €960,473 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
BridgeBio Pharma | Attruby | ATTR-CM Ashley Cudini Qualification | 5% €421,260 19% €80,039 Critical Vel: 2/20 | DM: 2/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10
Fedgroup Johannes Vonhuelsen Qualification €0 19% €0 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Janssen - Commercial Data Science Qualification €300,000 19% €57,000 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Medgate Daniel Nathrath Qualification €0 19% €0 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Ontario Enhancements - Suicide Pop Up - Delivery Simon Wolpert Qualification | 5% €247,587 19% €47,041 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Ontario SOW9 - Health Care Connect (Primary Care A Simon Wolpert Proposal | 30% €30,948 19% €5,880 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Ontario Upsell - FTI + Concierge Simon Wolpert Qualification €7,000,000 19% €1,330,000 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
Saudi MoH Saned platform Daniel Nathrath Qualification €900,000 19% €171,000 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10
VA (EHR Modernization Integration Office) Simon Wolpert Qualification €15,333,864 19% €2,913,434 Critical Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10